eLetters

322 e-Letters

  • Detection of anti-nuclear antibodies. Added-value of solid phase assay?
    Xavier Bossuyt

    Dear Editor,

    Agmon-Levin et al.[1] formulated recommendations for the assessment of anti-nuclear antibodies (ANA). Indirect immunofluorescence (IIF) is considered the reference method for ANA screening, which is in agreement with the ACR position statement[2]. The recommendations are based on current knowledge and expert experience.
    However, as recognized by Meroni and Schur[2], no well-planned studies comp...

    Show More
  • Response to Feldtkeller et al Letter
    Irene van der Horst-Bruinsma

    Dear Editor,

    We would like to thank you for your remarks regarding our manuscript van der Horst-Bruinsma et al Ann Rheum Dis 2013;72:1221- 1224.[1] We do agree that in ankylosing spondylitis, onset is more accurately described by onset of symptoms as opposed to age at diagnosis. Unfortunately, we did not collect the time-of-symptom-onset data in three of the four studies in this analysis. Thus, we used the age at d...

    Show More
  • Authors' response to van der Maas et al
    Kazuki Yoshida

    Dear Editor,

    We would like to thank van der Maas and colleagues for their interest in and useful feedback on our review [1]. They raise several important points. First, regarding the interpretation of the studies included in the review, we focused on studies examining discontinuation of biologic disease modifying antirheumatic drugs (DMARDs) that examined patient outcomes. Thus, we had difficulty in fitting a taperin...

    Show More
  • Biologic discontinuation studies: a systematic review of methods; comment on the article by Yoshida et al.
    Aatke van der Maas

    Dear Editor,

    Yoshida et al present an overview of different designs and 'failure definitions' in biologic discontinuation studies in rheumatoid arthritis (RA).[1] We feel it is a very important review, as the number of discontinuation studies is increasing and therefore awareness of the heterogeneity in these study designs as demonstrated in this review is essential. We have however a few comments. Firstly, one of...

    Show More
  • Response to Dr Bolland's eLetter
    Jean-Yves Reginster

    Dear Editor,

    The work carried out by the authors on calcium and the cardiovascular risk is of primary importance. We thank the authors for questions and comments on the SEKOIA study, safety being a primary concern for us.
    The number of emergent adverse events reported in SEKOIA study was similar in the 3 treatments groups: 85.8%, 87.9% and 86.5% in the SrRan 1g, SrRan 2g and placebo groups as well as the number...

    Show More
  • Response
    Marie Condon

    Dear Editor,

    Many thanks for the very interesting letter from Abud-Mendoza, highlighting their work in Mexico where they have successfully used rituximab in the treatment of both lupus nephritis and systemic lupus.
    Their initial report from 2006 [1] used rituximab as a treatment for refractory lupus nephritis and showed very detailed work on lymphocytes after rituximab administration. Supporting our data, th...

    Show More
  • Re:Evidence in Support of the Validity of the TNF Brake Hypothesis
    Xenofon Baraliakos

    Response to the eLetter by Maksymowych WP, entitled ?Evidence in Support of the Validity of the TNF Brake Hypothesis"

    Dear Editor,

    with great interest we read the Letter by our colleague W.Maksymowych, entitled ?Evidence in Support of the Validity of the TNF Brake Hypothesis", which commented on our paper "Continuous increase in the rate of new bone formation in patients with ankylosing spondylitis (A...

    Show More
  • Evidence in Support of the Validity of the TNF Brake Hypothesis
    Walter P. Maksymowych

    Dear Editor,

    Re: Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Baraliakos X, Haibel H, Listing J, Sieper J,Braun J. 1doi:10.1136/annrheumdis-2012-202698

    I read with interest the findings of an observational cohort study in which patients with ankylosing spondylitis (AS) receiving infliximab (IFX)...

    Show More
  • Authors' response re:Abatacept in relapsing polychondritis
    Stanford Peng

    Dear Editor,

    We were pleased to learn of Moulis et al.'s update on their experience with abatacept in three RP patients, particularly since their disease manifestations reflected the same manifestations suggested in our study to be of greatest interest for abatacept: chondritis and peripheral arthritis. Interestingly one patient achieved a complete, while another achieved only a partial, corticosteroid-sparing...

    Show More
  • Abatacept in relapsing polychondritis
    Guillaume Moulis

    Dear Editor,

    We read with great interest the open clinical trial of four relapsing polychondritis (RP) patients treated with abatacept by Peng and Rodriguez recently published in the Annals of the Rheumatic Diseases (1). Indeed, as the authors pointed out, there is rational to block T-cell pathway in this disease, though the biologic agents most used as second-line therapy after corticosteroids (CS) are pro-inflamm...

    Show More

Pages